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Abstracts A67
model (ﬁ ve-year horizon, three-month cycles) evaluating NSAID treatment in OA, the
overall AE related costs and their constituents associated with celecoxib and ibuprofen 
treatment were quantiﬁ ed and compared. The individual costs (11 in total) were
aggregated to four categories relevant to OA treatment: (i) costs directly attributable
to clinically signiﬁ cant gastrointestinal (GI) AEs; (ii) costs directly attributable to dys-
pepsia; (iii) costs associated with myocardial infarction (MI); and (iv) co-medication
(mainly proton pump inhibitors) costs. The model, which has a health care perspective,
was populated with UK data and a discount rate of 3.5% per year was used. Except 
for the MI risks which were adjusted for age, all absolute and relative risks were taken 
from a meta-analysis in a recent NICE HTA report. Costs were aggregated to 1000 
patients on treatment. RESULTS: Although 9 of the 11 adverse event related individual 
costs were lower with celecoxib than ibuprofen treatment, the overall cost difference 
(a42,640 in favor of celecoxib) was attenuated by the relatively high MI related costs 
associated with celecoxib treatment (a92,734). CONCLUSIONS: Whilst the GI safety 
proﬁ le of celecoxib yields cost advantages, the MI costs associated with celecoxib 
treatment weakens the effect on overall adverse event related costs resulting from the
beneﬁ cial GI safety proﬁ le.
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OBJECTIVES: Eight million women and two million men are afﬂ icted with osteopo-
rosis in the United States. There are additional 34 million people exhibiting low bone
mass at risk for the development of osteoporosis. The purpose of this study was to
describe the drug utilization and spending trends for bisphosphonate and other alter-
native osteoporosis medications in the Medicaid program. METHODS: Using a ret-
rospective and descriptive study, Medicaid pharmacy claims data extracted from the
Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 regarding
quarterly number of prescriptions, units usage, reimbursement amount, and reim-
bursement per prescription for the oral bisphosphonates, injectable bisphosphonates, 
and alternative osteoporosis medications. Drugs were identiﬁ ed using their respective 
national drug codes (NDC). RESULTS: Risedronate accounted for 27% of all bisphos-
phonates prescriptions while alendronate accounted for the vast majority of bisphos-
phonate prescriptions with approximately 70% of the market over the 1991–2007 
timeframe. Both alendronate and risedronate together accounted for approximately
92% of all reimbursements for both oral and injectable bisphosphonates during the 
study period. Alendronate’s market share, as measured by total reimbursement, has 
been steadily declining from third quarter of 2004 to the third quarter of 2007, 
accounting for approximately 57% of total reimbursements, contrary to the roughly
83% of all reimbursements from the fourth quarter of 1996 to the second quarter of 
2004. CONCLUSIONS: Market share for the leading brand drugs has steadily
declined with the introduction of generic competition as measured by overall utiliza-
tion and total reimbursement, such as risedronate competing with alendronate in the 
bisphosphonate market and raloxifene competing with calcitonin-salmon in the alter-
native osteoporosis market. Examination of the Medicaid data also revealed a strident 
market shift in utilization following the fourth quarter of 2005, resulting from the
switching of dual eligibles from Medicaid to Medicare Part D.
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OBJECTIVES: To compare the traditionally used approach for fracture risk assess-
ment in cost-effectiveness analysis (CEA) compared to the use of FRAX models 
based on multiple individual clinical risk factors (CRFs) using the osteoporosis treat-
ment bazedoxifene. METHODS: In CEA of osteoporosis the fracture risk has tradi-
tionally been calculated with risk-adjustments based on age, bone mineral density
(BMD) and prior fracture. The treatment effect has been derived from clinical trials 
and the same efﬁ cacy has been assumed irrespective of the fracture risk of the popula-
tion. A novel approach to fracture risk assessment considers the contribution of 8 
individual CRFs on fracture risk and mortality using the FRAX-tool. The application 
of FRAX to clinical trial populations has shown that treatment efﬁ cacy increases
with higher fracture risk. The cost-effectiveness was estimated in a Markov cohort 
model with US data using a health care perspective. The CEA compared the osteopo-
rosis treatment bazedoxifene (BZA) to no treatment in women with a T-score for
femoral neck BMD of 2.5SD and previous fracture. Using the old approach BZA 
was set to reduce the risk of vertebral fracture by 42% based on the overall analysis 
of the phase III study. Using the FRAX-approach the vertebral fracture risk reduction
varied depending on pre-hoc fracture probability in the target population and was 
estimated at 59%. The relative risk of a vertebral fracture compared to the general
population was 3.96 and 1.82 with the old and FRAX-approach, respectively. 
RESULTS: The cost per QALY gained with bazedoxifene treatment was estimated at 
$54,712 using the old approach and $33,650 using the FRAX-approach. This is due
to differences in the assessment of fracture risk efﬁ cacy, fracture risk and mortality. 
CONCLUSIONS: The advent of more accurate assessment of fracture risk assessment
and its use as a determinant of efﬁ cacy has important consequences for CEA.
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OBJECTIVES: Knee osteoarthrosis is a multifactorial, progressive and incurable rheu-
matic ailment; most treatments look for a maximum recovery of mobility and func-
tionality of the knee joint, with a minimum risk possibility. Due to its high cost and 
invasive character, gonarthrosis surgical treatment is reserved, according to the clinical
practice guidance available in Mexico, for severe pain and joint functionality limita-
tion cases; deﬁ ned as knee osteoarthrosis present in IV degree, or functional class III
onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs.
intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. 
METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypotheti-
cal cohort behavior of patients with severe knee osteoarthrosis for a period of two 
years, from the perspective of the health service supplier. Costs were estimated using 
prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US 
dollar). RESULTS: With Hylan G-F 20, 94.6% of patients did not require surgery 
during the analysis period vs. 50%, in the case of those under intraarticular steroid 
treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular ste-
roids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 
and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as
dominant alternative. Different sensitivity analyses corroborate the dominance rela-
tionship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS:
Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment 
to withhold surgery in patients with severe knee osteoarthrosis.
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OBJECTIVES: To determine the cost-effectiveness of etanercept plus methotrexate
(MTX) versus rituximab plus MTX in the treatment of rheumatoid arthritis (RA)
patients from a payer’s perspective in Mexico. METHODS: A literature-based decision 
analytic model was developed to compare the cost and effectiveness of etanercept
25 mg twice-weeklyMTX versus rituximab 2 r 500 mg infusionMTX and ritux-
imab 2 r 1000 mg infusionMTX (labeled dosage) in RA patients with an inadequate
response to disease-modifying anti-rheumatic drugs. The primary measure of clinical
outcomes was based on remission (Disease Activity Score 28 joint count 2.6). The 
model incorporated major and minor infectious events, discontinuation due to inade-
quate efﬁ cacy or adverse event, and rituximab re-treatment within the one year time-
horizon. Data from clinical trials (TEMPO and SERENE) were used. Drug and 
resource-use costs were based on government-reported public costs. Sensitivity analy-
sis was conducted by varying efﬁ cacy and cost parameters by o 30%. RESULTS:
The annual total therapy cost for rituximab was MEX$74,543 (2 r 500 mg) 
and MEX$137,223 (2 r 1000 mg), and MEX$119,133 for etanercept. The incre-
mental cost-effectiveness ratio (ICER) of etanercept vs. rituximab 2 r 500 mg was 
MEX$201,581 per additional patient achieving remission. Etanercept was cost saving 
compared to rituximab 2 r 1000 mg. With a hypothetical budget of MEX$10,000,000
for rituximab or etanercept, the number of patients achieving remission would be 7
(2 r 500 mg) and 4 (2 r 1000 mg) for rituximab and 23 for etanercept. Sensitivity
analysis showed that etanercept continued to have more patients achieving remission 
than rituximab (for both dosage forms) even if drug cost and efﬁ cacy were varied o
30%, given a deﬁ ned budget. CONCLUSIONS: The results suggest that etanercept 
appears to be cost-effective compared to rituximab. For the labeled and commonly 
used rituximab dosage (2 r 1000 mg), etanercept appears to be a cost-saving alterna-
tive. These ﬁ ndings were robust for plausible ranges of effectiveness and drug acquisi-
tion costs.
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OBJECTIVES: Purpose of the study was to conduct a cost-efﬁ cacy analyses between 
three combinations of Tumor Necrosis Factor-Alpha agents used in treatment of 
rheumatoid arthritis. The study compared adalimumab plus methotrexate 
(ADALMTX), inﬂ iximab plus methotrexate (INFLMTX), etanercept plus metho-
trexate (ETANMTX), with methotrexate (MTX) monotherapy (control). METHODS:
The study was conducted from the patients’ perspective. Costs calculated for a period 
of one year included direct medical costs (drug acquisition costs, monitoring costs,
and adverse drug event costs) and indirect costs (estimated using human capital 
approach). All costs were calculated in 2007 dollars and adjusted using a discounting
factor of 3%. Outcome of therapeutic options was measured using the American 
